Levo Medical Corporation

Levo Medical Corporation develops neuroscience-based therapeutic devices for tinnitus management. The company manufactures the Levo Gen 2 system, a personalized therapy platform that replicates individual tinnitus sounds and monitors patient progress using the clinically validated Tinnitus Functional Index (TFI). The therapy is supported by over 25 years of clinical research and U.S. clinical trials demonstrating sustained symptom reduction and improved quality of life for patients with subjective idiopathic tinnitus. Levo Gen 2 is pending FDA 510(k) clearance in the United States, with Levo Gen 1 currently available. The company positions its offering as a medically guided therapy that includes specialized equipment, ongoing clinical monitoring, and professional support. Treatment is personalized based on individual patient evaluation and needs. The platform serves patients referred by or working with ENT specialists and healthcare professionals who can offer the therapy at their clinics. Pricing varies by individual case and is determined during clinical consultation.